Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
NCT01460862 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2021-12-07
Summary
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
More Related Trials
-
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
NCT00670930 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
NCT00482508 ·Status: COMPLETED ·Phase: PHASE3
-
ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression
NCT06869382 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
NCT01703312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Retrospective Study for Description of The Use Of Omalizumab In Patients With Difficult To Control Asthma
NCT01397760 ·Status: UNKNOWN
-
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
NCT01922037 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Omalizumab in Moderate to Severe Bronchial Asthma
NCT00232050 ·Status: COMPLETED ·Phase: PHASE3
-
Omalizumab Before Onset of Exacerbations
NCT05332067 ·Status: RECRUITING ·Phase: PHASE2
-
Omalizumab in Non-atopic Asthma
NCT01113437 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma
NCT00133042 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
NCT00546143 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
NCT00870584 ·Status: COMPLETED ·Phase: PHASE4
-
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
NCT00567476 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
NCT00180011 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
NCT00219323 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)
NCT00666679 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
NCT05424523 ·Status: COMPLETED
-
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
NCT00434434 ·Status: COMPLETED ·Phase: PHASE2
-
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
NCT01430403 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma
NCT00252135 ·Status: COMPLETED
-
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
NCT00454051 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
NCT00314574 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Omalizumab Compared to Non-Omalizumab Treatment in Asthma Patients
NCT02921178 ·Status: UNKNOWN
-
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
NCT03299686 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
NCT00264849 ·Status: COMPLETED ·Phase: PHASE4